Streetbeat News

Regulatory

DMA

Destra Multi-Alternative Fund (DMA) has updated its portfolio holdings disclosure practices. The Fund will now disclose its complete portfolio holdings on its website at the end of each month with a minimum lag time of ten calendar days. Previously, only the top 10 holdings were disclosed monthly, and full portfolio holdings were released quarterly with up to a 60-day lag.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 2:04 pm

EXEL

Exelixis, Inc. (NASDAQ:EXEL) announced initial results from an expansion cohort of STELLAR-001 evaluating zanzalintinib in patients with previously treated clear cell renal cell carcinoma (ccRCC). The results demonstrated an objective response rate of 38% and a disease control rate of 88%. The findings were presented at the 2023 International Kidney Cancer Symposium (IKCS). The results are encouraging for patients with advanced kidney cancer who have exhausted their treatment options.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 2:03 pm

COP

ConocoPhillips (NYSE:COP) has received judicial approval for its $7.5 billion Willow oil project in Alaska, which is estimated to hold around 600 million barrels of oil. The project, which faced opposition from environmental advocates, is expected to produce approximately 180,000 barrels of oil daily. The company is preparing for on-site operations, which could start as early as the upcoming winter season.

Portfolio Pulse from Shivani Kumaresan

November 10, 2023 | 1:54 pm

CYTO

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has received an 'Intention to Grant' notice from the European Patent Office for its patent application titled 'Intranasal Composition Comprising Betahistine'. The patent, expected to remain valid until February 2038, will provide key intellectual property protection for the company's intranasal betahistine program (AM-125) in Europe. The patent has been granted in around 50 countries worldwide, including key markets in North America and Europe.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:47 pm

MOTS

Motus GI announced that the Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:40 pm

VALN

The FDA has approved Valneva SE's (NASDAQ:VALN) single-dose Chikungunya vaccine for individuals aged 18 and above. The company plans to start selling the vaccine, Ixchiq, in the U.S. early next year. This makes Ixchiq the world's first licensed Chikungunya vaccine. Valneva's shares are up 6.04% premarket on the news.

Portfolio Pulse from Vandana Singh

November 10, 2023 | 1:37 pm

SGMT

Sagimet Biosciences has presented preclinical results that show the therapeutic potential of its FASN inhibitor in combination with semaglutide. The combination treatment improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver fibrosis. The FASCINATE-2 Phase 2b clinical trial of denifanstat in F2-F3 NASH patients is fully enrolled and is on track to report week 52 topline results in the first quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:31 pm

BPMC

Blueprint Medicines has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency, recommending the approval of Ayvakyt (Avapritinib) for Indolent Systemic Mastocytosis.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:30 pm

TAK

Takeda Pharmaceutical Co Ltd (NYSE:TAK) has received FDA approval for Adzynma, a therapy for congenital thrombotic thrombocytopenic purpura (cTTP), a rare blood clotting disorder. The approval was supported by data from a Phase 3 trial and a continuation trial. This comes after the FDA's recent approval of Takeda's Fruzaqla for metastatic colorectal cancer. TAK shares are up 1.32% premarket.

Portfolio Pulse from Vandana Singh

November 10, 2023 | 1:19 pm

AQST

Aquestive Therapeutics, Inc. (NASDAQ:AQST) will present two posters at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, showcasing positive data from pharmacokinetic and pharmacodynamic studies of Anaphylm™ (epinephrine) Sublingual Film. The company's CEO, Dan Barber, expressed excitement about the results and the potential of Anaphylm for the treatment of acute allergic reactions, pending FDA approval.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:07 pm